Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential

Constantine E Kosmas,1 Alba Muñoz Estrella,2 Andreas Skavdis,3 Edilberto Peña Genao,4 Ian Martinez,5 Eliscer Guzman1 1Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA; 2Department of Medicine, Mount Sinai St. Luke’s-West Hospit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kosmas CE, Muñoz Estrella A, Skavdis A, Peña Genao E, Martinez I, Guzman E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	proprotein convertase subtilisin kexin 9 (pcsk-9) inclisiran hypercholesterolemia cardiovascular disease (cvd). Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/75ef66b9d431498fa4cba7a4b9c67c70
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75ef66b9d431498fa4cba7a4b9c67c70
record_format	dspace
spelling	oai:doaj.org-article:75ef66b9d431498fa4cba7a4b9c67c702021-12-02T11:38:23ZInclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential1178-203Xhttps://doaj.org/article/75ef66b9d431498fa4cba7a4b9c67c702020-10-01T00:00:00Zhttps://www.dovepress.com/inclisiran-for-the-treatment-of-cardiovascular-disease-a-short-review--peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XConstantine E Kosmas,1 Alba Muñoz Estrella,2 Andreas Skavdis,3 Edilberto Peña Genao,4 Ian Martinez,5 Eliscer Guzman1 1Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA; 2Department of Medicine, Mount Sinai St. Luke’s-West Hospital, New York, NY, USA; 3School of Medicine, University of Athens, Athens, Greece; 4Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA; 5Department of Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USACorrespondence: Constantine E Kosmas Tel +1-646-734-7969Email cekosmas1@gmail.comAbstract: Proprotein convertase subtilisin kexin 9 (PCSK-9)-targeting therapy has arisen as a new line for the treatment of hyperlipidemia. Inclisiran is a double-stranded small RNA molecule that works by blocking the transcription of PCSK-9, leading to a reduction of PCSK9 levels in the hepatocytes, resulting in an increased expression of low-density lipoprotein (LDL) receptors in the hepatocyte membrane and, as a consequence, it reduces the circulating levels of LDL cholesterol (LDL-C). Compared to the other LDL-C-lowering medications, such as statins, ezetimibe and PCSK-9 inhibitors, inclisiran proposes an infrequent dosing of twice a year, while simultaneously providing a significant reduction of LDL-C. Its prolonged effect offers an advantage against medication non-compliance, which is one of the main causes for not achieving LDL-C goals with standard therapy. Inclisiran has also proven to have a relatively safe profile with adverse effects occurring in similar frequency as with placebo. This review aims to present and discuss the current clinical and scientific data pertaining to the role of inclisiran in the management of hypercholesterolemia and treatment of cardiovascular disease (CVD).Keywords: proprotein convertase subtilisin kexin 9, PCSK-9, inclisiran, hypercholesterolemia, cardiovascular disease, CVDKosmas CEMuñoz Estrella ASkavdis APeña Genao EMartinez IGuzman EDove Medical Pressarticleproprotein convertase subtilisin kexin 9 (pcsk-9)inclisiranhypercholesterolemiacardiovascular disease (cvd).Therapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 16, Pp 1031-1037 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	proprotein convertase subtilisin kexin 9 (pcsk-9) inclisiran hypercholesterolemia cardiovascular disease (cvd). Therapeutics. Pharmacology RM1-950
spellingShingle	proprotein convertase subtilisin kexin 9 (pcsk-9) inclisiran hypercholesterolemia cardiovascular disease (cvd). Therapeutics. Pharmacology RM1-950 Kosmas CE Muñoz Estrella A Skavdis A Peña Genao E Martinez I Guzman E Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
description	Constantine E Kosmas,1 Alba Muñoz Estrella,2 Andreas Skavdis,3 Edilberto Peña Genao,4 Ian Martinez,5 Eliscer Guzman1 1Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA; 2Department of Medicine, Mount Sinai St. Luke’s-West Hospital, New York, NY, USA; 3School of Medicine, University of Athens, Athens, Greece; 4Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA; 5Department of Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USACorrespondence: Constantine E Kosmas Tel +1-646-734-7969Email cekosmas1@gmail.comAbstract: Proprotein convertase subtilisin kexin 9 (PCSK-9)-targeting therapy has arisen as a new line for the treatment of hyperlipidemia. Inclisiran is a double-stranded small RNA molecule that works by blocking the transcription of PCSK-9, leading to a reduction of PCSK9 levels in the hepatocytes, resulting in an increased expression of low-density lipoprotein (LDL) receptors in the hepatocyte membrane and, as a consequence, it reduces the circulating levels of LDL cholesterol (LDL-C). Compared to the other LDL-C-lowering medications, such as statins, ezetimibe and PCSK-9 inhibitors, inclisiran proposes an infrequent dosing of twice a year, while simultaneously providing a significant reduction of LDL-C. Its prolonged effect offers an advantage against medication non-compliance, which is one of the main causes for not achieving LDL-C goals with standard therapy. Inclisiran has also proven to have a relatively safe profile with adverse effects occurring in similar frequency as with placebo. This review aims to present and discuss the current clinical and scientific data pertaining to the role of inclisiran in the management of hypercholesterolemia and treatment of cardiovascular disease (CVD).Keywords: proprotein convertase subtilisin kexin 9, PCSK-9, inclisiran, hypercholesterolemia, cardiovascular disease, CVD
format	article
author	Kosmas CE Muñoz Estrella A Skavdis A Peña Genao E Martinez I Guzman E
author_facet	Kosmas CE Muñoz Estrella A Skavdis A Peña Genao E Martinez I Guzman E
author_sort	Kosmas CE
title	Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
title_short	Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
title_full	Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
title_fullStr	Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
title_full_unstemmed	Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
title_sort	inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/75ef66b9d431498fa4cba7a4b9c67c70
work_keys_str_mv	AT kosmasce inclisiranforthetreatmentofcardiovasculardiseaseashortreviewontheemergingdataandtherapeuticpotential AT munozestrellaa inclisiranforthetreatmentofcardiovasculardiseaseashortreviewontheemergingdataandtherapeuticpotential AT skavdisa inclisiranforthetreatmentofcardiovasculardiseaseashortreviewontheemergingdataandtherapeuticpotential AT penagenaoe inclisiranforthetreatmentofcardiovasculardiseaseashortreviewontheemergingdataandtherapeuticpotential AT martinezi inclisiranforthetreatmentofcardiovasculardiseaseashortreviewontheemergingdataandtherapeuticpotential AT guzmane inclisiranforthetreatmentofcardiovasculardiseaseashortreviewontheemergingdataandtherapeuticpotential
_version_	1718395766771286016

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential

Ejemplares similares